Nandrolone decanoate administration does not attenuate muscle atrophy during a short period of disuse

Astrid M.H. Horstman, Evelien M.P. Backx, Joey S.J. Smeets, Gabriel N. Marzuca-Nassr, Janneau van Kranenburg, Douwe de Boer, John Dolmans, Tim Snijders, Lex B. Verdijk, Lisette C.P.G.M. de Groot, Luc J.C. van Loon

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

BACKGROUND: A few days of bed rest or immobilization following injury, disease, or surgery can lead to considerable loss of skeletal muscle mass and strength. It has been speculated that such short, successive periods of muscle disuse may be largely responsible for the age-related loss of muscle mass throughout the lifespan. OBJECTIVE: To assess whether a single intramuscular injection of nandrolone decanoate prior to immobilization can attenuate the loss of muscle mass and strength in vivo in humans. DESIGN, SETTING AND PARTICIPANTS: Thirty healthy (22 ± 1 years) men were subjected to 7 days of one-legged knee immobilization by means of a full leg cast with (NAD, n = 15) or without (CON, n = 15) prior intramuscular nandrolone decanoate injection (200 mg). MEASURES: Before and immediately after immobilization, quadriceps muscle cross-sectional area (CSA) (by means of single-slice computed tomography (CT) scans of the upper leg) and one-legged knee extension strength (one-repetition maximum [1-RM]) were assessed for both legs. Furthermore, muscle biopsies from the immobilized leg were taken before and after immobilization to assess type I and type II muscle fiber cross-sectional area. RESULTS: Quadriceps muscle CSA decreased during immobilization in both CON and NAD (-6 ± 1% and -6 ± 1%, respectively; main effect of time P<0.01), with no differences between the groups (time × treatment interaction, P = 0.59). Leg muscle strength declined following immobilization (-6 ± 2% in CON and -7 ± 3% in NAD; main effect of time, P<0.05), with no differences between groups (time × treatment interaction, P = 0.55). CONCLUSIONS: This is the first study to report that nandrolone decanoate administration does not preserve skeletal muscle mass and strength during a short period of leg immobilization in vivo in humans.

LanguageEnglish
Pagese0210823
JournalPLoS ONE
Volume14
Issue number1
DOIs
Publication statusPublished - 1 Jan 2019

Fingerprint

nandrolone
muscular atrophy
Muscular Atrophy
Immobilization
Muscle
legs
Leg
muscles
Muscle Strength
knees
NAD
skeletal muscle
Quadriceps Muscle
Muscles
muscle strength
Knee
Skeletal Muscle
Slow-Twitch Muscle Fibers
Fast-Twitch Muscle Fibers
intramuscular injection

Cite this

Horstman, A. M. H., Backx, E. M. P., Smeets, J. S. J., Marzuca-Nassr, G. N., van Kranenburg, J., de Boer, D., ... van Loon, L. J. C. (2019). Nandrolone decanoate administration does not attenuate muscle atrophy during a short period of disuse. PLoS ONE, 14(1), e0210823. https://doi.org/10.1371/journal.pone.0210823
Horstman, Astrid M.H. ; Backx, Evelien M.P. ; Smeets, Joey S.J. ; Marzuca-Nassr, Gabriel N. ; van Kranenburg, Janneau ; de Boer, Douwe ; Dolmans, John ; Snijders, Tim ; Verdijk, Lex B. ; de Groot, Lisette C.P.G.M. ; van Loon, Luc J.C. / Nandrolone decanoate administration does not attenuate muscle atrophy during a short period of disuse. In: PLoS ONE. 2019 ; Vol. 14, No. 1. pp. e0210823.
@article{5625e9073f47403abb255a0ffe6c4e87,
title = "Nandrolone decanoate administration does not attenuate muscle atrophy during a short period of disuse",
abstract = "BACKGROUND: A few days of bed rest or immobilization following injury, disease, or surgery can lead to considerable loss of skeletal muscle mass and strength. It has been speculated that such short, successive periods of muscle disuse may be largely responsible for the age-related loss of muscle mass throughout the lifespan. OBJECTIVE: To assess whether a single intramuscular injection of nandrolone decanoate prior to immobilization can attenuate the loss of muscle mass and strength in vivo in humans. DESIGN, SETTING AND PARTICIPANTS: Thirty healthy (22 ± 1 years) men were subjected to 7 days of one-legged knee immobilization by means of a full leg cast with (NAD, n = 15) or without (CON, n = 15) prior intramuscular nandrolone decanoate injection (200 mg). MEASURES: Before and immediately after immobilization, quadriceps muscle cross-sectional area (CSA) (by means of single-slice computed tomography (CT) scans of the upper leg) and one-legged knee extension strength (one-repetition maximum [1-RM]) were assessed for both legs. Furthermore, muscle biopsies from the immobilized leg were taken before and after immobilization to assess type I and type II muscle fiber cross-sectional area. RESULTS: Quadriceps muscle CSA decreased during immobilization in both CON and NAD (-6 ± 1{\%} and -6 ± 1{\%}, respectively; main effect of time P<0.01), with no differences between the groups (time × treatment interaction, P = 0.59). Leg muscle strength declined following immobilization (-6 ± 2{\%} in CON and -7 ± 3{\%} in NAD; main effect of time, P<0.05), with no differences between groups (time × treatment interaction, P = 0.55). CONCLUSIONS: This is the first study to report that nandrolone decanoate administration does not preserve skeletal muscle mass and strength during a short period of leg immobilization in vivo in humans.",
author = "Horstman, {Astrid M.H.} and Backx, {Evelien M.P.} and Smeets, {Joey S.J.} and Marzuca-Nassr, {Gabriel N.} and {van Kranenburg}, Janneau and {de Boer}, Douwe and John Dolmans and Tim Snijders and Verdijk, {Lex B.} and {de Groot}, {Lisette C.P.G.M.} and {van Loon}, {Luc J.C.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1371/journal.pone.0210823",
language = "English",
volume = "14",
pages = "e0210823",
journal = "PLoS ONE",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "1",

}

Horstman, AMH, Backx, EMP, Smeets, JSJ, Marzuca-Nassr, GN, van Kranenburg, J, de Boer, D, Dolmans, J, Snijders, T, Verdijk, LB, de Groot, LCPGM & van Loon, LJC 2019, 'Nandrolone decanoate administration does not attenuate muscle atrophy during a short period of disuse', PLoS ONE, vol. 14, no. 1, pp. e0210823. https://doi.org/10.1371/journal.pone.0210823

Nandrolone decanoate administration does not attenuate muscle atrophy during a short period of disuse. / Horstman, Astrid M.H.; Backx, Evelien M.P.; Smeets, Joey S.J.; Marzuca-Nassr, Gabriel N.; van Kranenburg, Janneau; de Boer, Douwe; Dolmans, John; Snijders, Tim; Verdijk, Lex B.; de Groot, Lisette C.P.G.M.; van Loon, Luc J.C.

In: PLoS ONE, Vol. 14, No. 1, 01.01.2019, p. e0210823.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Nandrolone decanoate administration does not attenuate muscle atrophy during a short period of disuse

AU - Horstman, Astrid M.H.

AU - Backx, Evelien M.P.

AU - Smeets, Joey S.J.

AU - Marzuca-Nassr, Gabriel N.

AU - van Kranenburg, Janneau

AU - de Boer, Douwe

AU - Dolmans, John

AU - Snijders, Tim

AU - Verdijk, Lex B.

AU - de Groot, Lisette C.P.G.M.

AU - van Loon, Luc J.C.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - BACKGROUND: A few days of bed rest or immobilization following injury, disease, or surgery can lead to considerable loss of skeletal muscle mass and strength. It has been speculated that such short, successive periods of muscle disuse may be largely responsible for the age-related loss of muscle mass throughout the lifespan. OBJECTIVE: To assess whether a single intramuscular injection of nandrolone decanoate prior to immobilization can attenuate the loss of muscle mass and strength in vivo in humans. DESIGN, SETTING AND PARTICIPANTS: Thirty healthy (22 ± 1 years) men were subjected to 7 days of one-legged knee immobilization by means of a full leg cast with (NAD, n = 15) or without (CON, n = 15) prior intramuscular nandrolone decanoate injection (200 mg). MEASURES: Before and immediately after immobilization, quadriceps muscle cross-sectional area (CSA) (by means of single-slice computed tomography (CT) scans of the upper leg) and one-legged knee extension strength (one-repetition maximum [1-RM]) were assessed for both legs. Furthermore, muscle biopsies from the immobilized leg were taken before and after immobilization to assess type I and type II muscle fiber cross-sectional area. RESULTS: Quadriceps muscle CSA decreased during immobilization in both CON and NAD (-6 ± 1% and -6 ± 1%, respectively; main effect of time P<0.01), with no differences between the groups (time × treatment interaction, P = 0.59). Leg muscle strength declined following immobilization (-6 ± 2% in CON and -7 ± 3% in NAD; main effect of time, P<0.05), with no differences between groups (time × treatment interaction, P = 0.55). CONCLUSIONS: This is the first study to report that nandrolone decanoate administration does not preserve skeletal muscle mass and strength during a short period of leg immobilization in vivo in humans.

AB - BACKGROUND: A few days of bed rest or immobilization following injury, disease, or surgery can lead to considerable loss of skeletal muscle mass and strength. It has been speculated that such short, successive periods of muscle disuse may be largely responsible for the age-related loss of muscle mass throughout the lifespan. OBJECTIVE: To assess whether a single intramuscular injection of nandrolone decanoate prior to immobilization can attenuate the loss of muscle mass and strength in vivo in humans. DESIGN, SETTING AND PARTICIPANTS: Thirty healthy (22 ± 1 years) men were subjected to 7 days of one-legged knee immobilization by means of a full leg cast with (NAD, n = 15) or without (CON, n = 15) prior intramuscular nandrolone decanoate injection (200 mg). MEASURES: Before and immediately after immobilization, quadriceps muscle cross-sectional area (CSA) (by means of single-slice computed tomography (CT) scans of the upper leg) and one-legged knee extension strength (one-repetition maximum [1-RM]) were assessed for both legs. Furthermore, muscle biopsies from the immobilized leg were taken before and after immobilization to assess type I and type II muscle fiber cross-sectional area. RESULTS: Quadriceps muscle CSA decreased during immobilization in both CON and NAD (-6 ± 1% and -6 ± 1%, respectively; main effect of time P<0.01), with no differences between the groups (time × treatment interaction, P = 0.59). Leg muscle strength declined following immobilization (-6 ± 2% in CON and -7 ± 3% in NAD; main effect of time, P<0.05), with no differences between groups (time × treatment interaction, P = 0.55). CONCLUSIONS: This is the first study to report that nandrolone decanoate administration does not preserve skeletal muscle mass and strength during a short period of leg immobilization in vivo in humans.

U2 - 10.1371/journal.pone.0210823

DO - 10.1371/journal.pone.0210823

M3 - Article

VL - 14

SP - e0210823

JO - PLoS ONE

T2 - PLoS ONE

JF - PLoS ONE

SN - 1932-6203

IS - 1

ER -

Horstman AMH, Backx EMP, Smeets JSJ, Marzuca-Nassr GN, van Kranenburg J, de Boer D et al. Nandrolone decanoate administration does not attenuate muscle atrophy during a short period of disuse. PLoS ONE. 2019 Jan 1;14(1):e0210823. https://doi.org/10.1371/journal.pone.0210823